PharmaResearch Co., Ltd.

KOSDAQ 214450.KQ

PharmaResearch Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.08

PharmaResearch Co., Ltd. Debt to Equity Ratio is 0.08 for the year ending December 31, 2023, a -60.17% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • PharmaResearch Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.19, a -9.51% change year over year.
  • PharmaResearch Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.21, a 62.66% change year over year.
  • PharmaResearch Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.13, a 31.84% change year over year.
  • PharmaResearch Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.10, a -2.78% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
KOSDAQ: 214450.KQ

PharmaResearch Co., Ltd.

CEO Mr. Sang-Soo Jung
IPO Date July 24, 2015
Location South Korea
Headquarters 62, Pangyo-ro 255beon-gil
Employees 402
Sector Health Care
Industries
Description

PharmaResearch Co., Ltd. operates as a biopharmaceutical company in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; Rejuvenex cream, which treats the wound through rapid tissue regeneration; REJURAN HEALER, an intra dermal injection to enhance elasticity, turgidity, and tonicity of skin; Rejuran i and Rejuran s intra dermal or cannula injections; REJURAN moisturizer for daily skin protection; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel; REJURAN healing cream and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. It also provides D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; and CLEVIEL prime plus and contour plus with lidocaine medical devices, as well as CONJURAN medical devices. In addition, the company offers functional foods under the REJULINE, REJUSHINE, and REJULIGHT brands. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Seongnam, South Korea.

Similar companies

196170.KQ

ALTEOGEN Inc.

USD 209.72

3.60%

086900.KQ

Medy-Tox Inc.

USD 83.61

0.82%

096530.KQ

Seegene, Inc.

USD 17.02

-2.20%

068270.KS

Celltrion, Inc.

USD 125.83

1.12%

298380.KQ

ABL Bio Inc.

USD 21.07

1.40%

StockViz Staff

January 15, 2025

Any question? Send us an email